Buy 3000 SENSEONICS HLDGS INC COM (SENS)- PLEASE KEEP IN MIND THIS IS A GBA LONGSHOT PICK**** JUST BECAUSE WE HAVE NAILED A FEW OF THESE LONGSHOTS DOESN'T MEAN THIS ONE WILL WORK.... BUY SMALL HOPE FOR THE MOON!~SI
Too funny. One of my peeps gave me this lightning info about a huge insider buy at Moderna and I spent the morning looking for it.. It was CRSP!
Crispr director George buys $51.5M of shares Jul. 18, 2025 10:08 AM CRISPR Therapeutics AG (CRSP) Stock Crispr Therapeutics (NASDAQ:CRSP) has disclosed a $51.5 million stock purchase by board director Simeon George in an SEC filing. Crispr surged as much as 21%on Friday, marking its biggest intraday gain since February, after. The stock is now up around58.4%year-to-date.
Watch ugly step child of CRSP... Watch-->NTLA Intellia Therapeutics, Inc. $12.39 0.56(+4.73%)11:01 AM 07/18/25 NASDAQ |$USD |Realtime
Might be a stretch but watch BEAM here-- We are still not in this name>>>> Just seems too much on the come and Sickle Cell not the biggest target/ they do work with CRSP BEAM Beam Therapeutics Inc. $21.18 0.73(+3.57%)11:03 AM 07/18/25 NASDAQ |$USD |Realtime Company Profile Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Olli's is kinda immune to tariffs since they buy closeouts, but I think the stock has gotten a little ahead of itself here. Short idea: Olli's @ $132.50 Still a good stock though.
IFF is $75 Now one would think they might take a hit because of all the changes in ingredients that are being implicated... but if any company has the scale, R&D, and the deep pockets required to roll with the new changes, it would be IFF. The smaller players that supplied this stuff are probably toast. Possible long idea: International Flavors and Fragrances IFF @ $75
Hmmmm. ------------- IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale Joint venture Alpha Bio will use IFF’s proprietary Designed Enzymatic Biomaterials™ technology to provide high-performance, sustainable alternatives to fossil-based ingredients NEW YORK--(BUSINESS WIRE)--Mar. 27, 2025-- IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production will use IFF’s Designed Enzymatic Biomaterial™ (DEB) platform technology, integrated at the IFF biorefinery in Kotka, Finland. "Our partnership with Kemira has reached a significant milestone, enabling us to scale the production of groundbreaking biobased materials to meet the large and growing demand for high-performing and sustainable alternatives to fossil-derived polymers," said Erik Fyrwald, IFF CEO. "IFF’s DEB technology not only guarantees superior purity and consistency compared to traditional biopolymers but also enhances performance across various applications. This innovative approach allows us to combine biodegradability and material sustainability while maintaining cost efficiency and the high performance our customers expect." IFF’s DEB platform leverages biotechnology by using plant-based sugars and enzymes under mild process conditions to create biobased materials, which can be tailored for specific product applications. This allows manufacturers to replace traditional fossil-based synthetic polymers with more sustainable alternatives. This highly efficient enzymatic polymerization process converts plant sugars to biopolymers, offering superior purity and consistency compared to conventional synthetic polymers. These tailored biopolymers enhance product performance across diverse applications. “Since 2020, we’ve been collaborating with IFF using the DEB platform technology, which has allowed us to bring sustainable innovation to our key markets,” said Antti Salminen, CEO, Kemira Oyj. “The new joint venture will build on this initial success, enabling us to scale up production and provide new performance-competitive alternatives to fossil-based products in key markets, including paper and board packaging, paper coatings, and water treatment, while continuing to develop opportunities across other growth markets.” Operating as an independent entity in Kotka, Finland, the joint venture will manufacture a specific line of products enabled by DEB technology for exclusive use by IFF and Kemira. The creation of Alpha Bio is expected to generate approximately 30 direct new jobs in the Kotka area with additional job creation during the project’s construction phase.
Through these initiatives, IFF demonstrates a strong commitment to leveraging natural products and sustainable practices in its ingredient production, catering to the evolving preferences of consumers for healthier and more environmentally friendly options.
Trump threatens 15%-20% minimum tariff in any EU deal - report Jul. 18, 2025 1:14 PM U.S. President Donald Trump is seeking to impose a new baseline tariff of 15%-20% in trade talks with the European Union, rejecting the lower 10% framework that had underpinned weeks of negotiations, theFinancial Timesreported, citing three people familiar withthe matter. Even if a deal is struck, the Trump administration is now aiming to lock in tariffs above 10%, a U.S. official told theFT. " The Art Of The Spiel " I hope this is a clumsy negotiating tool to achieve 10%/// Push the EU too hard and they will throw us into a big correction. I don't want that but at the same time this tariff crap has become so annoying it's time somebody stood up to the bully and removed his robe...